Literature DB >> 24501405

Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.

Lise Schotte1, Mike Strauss, Bert Thys, Hadewych Halewyck, David J Filman, Mihnea Bostina, James M Hogle, Bart Rombaut.   

Abstract

UNLABELLED: Previously, we reported on the in vitro antiviral activity of single-domain antibody fragments (VHHs) directed against poliovirus type 1. Five VHHs were found to neutralize poliovirus type 1 in an in vitro setting and showed 50% effective concentrations (EC50s) in the nanomolar range. In the present study, we further investigated the mechanism of action of these VHHs. All five VHHs interfere at multiple levels of the viral replication cycle, as they interfere both with attachment of the virus to cells and with viral uncoating. The latter effect is consistent with their ability to stabilize the poliovirus capsid, as observed in a ThermoFluor thermal shift assay, in which the virus is gradually heated and the temperature causing 50% of the RNA to be released from the capsid is determined, either in the presence or in the absence of the VHHs. The VHH-capsid interactions were also seen to induce aggregation of the virus-VHH complexes. However, this observation cannot yet be linked to their mechanism of action. Cryo-electron microscopy (cryo-EM) reconstructions of two VHHs in complex with poliovirus type 1 show no conformational changes of the capsid to explain this aggregation. On the other hand, these reconstructions do show that the binding sites of VHHs PVSP6A and PVSP29F overlap the binding site for the poliovirus receptor (CD155/PVR) and span interfaces that are altered during receptor-induced conformational changes associated with cell entry. This may explain the interference at the level of cell attachment of the virus as well as their effect on uncoating. IMPORTANCE: The study describes the mechanism of neutralization and the capsid-stabilizing activity of five single-domain antibody fragments (VHHs) that have an in vitro neutralizing activity against poliovirus type 1. The results show that the VHHs interfere at multiple levels of the viral replication cycle (cell attachment and viral uncoating). These mechanisms are possibly shared by some conventional antibodies and may therefore provide some insight into the natural immune responses. Since the binding sites of two VHHs studied by cryo-EM are very similar to that of the receptor, the VHHs can be used as probes to study the authentic virus-cell interaction. The structures and conclusions in this study are original and raise interesting findings regarding virus-receptor interactions and the order of key events early in infection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24501405      PMCID: PMC3993733          DOI: 10.1128/JVI.03402-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Two distinct binding affinities of poliovirus for its cellular receptor.

Authors:  B M McDermott; A H Rux; R J Eisenberg; G H Cohen; V R Racaniello
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

2.  Three-dimensional structure of poliovirus receptor bound to poliovirus.

Authors:  D M Belnap; B M McDermott; D J Filman; N Cheng; B L Trus; H J Zuccola; V R Racaniello; J M Hogle; A C Steven
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

3.  Accurate determination of local defocus and specimen tilt in electron microscopy.

Authors:  Joseph A Mindell; Nikolaus Grigorieff
Journal:  J Struct Biol       Date:  2003-06       Impact factor: 2.867

4.  Cryo-electron microscopy reconstruction shows poliovirus 135S particles poised for membrane interaction and RNA release.

Authors:  Carmen Butan; David J Filman; James M Hogle
Journal:  J Virol       Date:  2013-11-20       Impact factor: 5.103

5.  Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae.

Authors:  K E Conrath; M Lauwereys; M Galleni; A Matagne; J M Frère; J Kinne; L Wyns; S Muyldermans
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

6.  Neutralization of poliovirus by a monoclonal antibody: kinetics and stoichiometry.

Authors:  J Icenogle; H Shiwen; G Duke; S Gilbert; R Rueckert; J Anderegg
Journal:  Virology       Date:  1983-06       Impact factor: 3.616

7.  Topographical studies on poliovirus capsid proteins by chemical modification and cross-linking with bifunctional reagents.

Authors:  K Wetz; K O Habermehl
Journal:  J Gen Virol       Date:  1979-08       Impact factor: 3.891

8.  Complexes of poliovirus serotypes with their common cellular receptor, CD155.

Authors:  Yongning He; Steffen Mueller; Paul R Chipman; Carol M Bator; Xiaozhong Peng; Valorie D Bowman; Suchetana Mukhopadhyay; Eckard Wimmer; Richard J Kuhn; Michael G Rossmann
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  Cholesterol removal by methyl-beta-cyclodextrin inhibits poliovirus entry.

Authors:  Pranav Danthi; Marie Chow
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

10.  Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.

Authors:  Anna L Salvati; Alessandra De Dominicis; Sabrina Tait; Andrea Canitano; Armin Lahm; Lucia Fiore
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

View more
  14 in total

Review 1.  Distinct antibody species: structural differences creating therapeutic opportunities.

Authors:  Serge Muyldermans; Vaughn V Smider
Journal:  Curr Opin Immunol       Date:  2016-02-27       Impact factor: 7.486

2.  Cryo-electron Microscopy Structures of Expanded Poliovirus with VHHs Sample the Conformational Repertoire of the Expanded State.

Authors:  Mike Strauss; Lise Schotte; Krishanthi S Karunatilaka; David J Filman; James M Hogle
Journal:  J Virol       Date:  2017-01-18       Impact factor: 5.103

3.  The enterovirus 71 procapsid binds neutralizing antibodies and rescues virus infection in vitro.

Authors:  Kristin L Shingler; Javier O Cifuente; Robert E Ashley; Alexander M Makhov; James F Conway; Susan Hafenstein
Journal:  J Virol       Date:  2014-11-26       Impact factor: 5.103

4.  Characterization of Poliovirus Neutralization Escape Mutants of Single-Domain Antibody Fragments (VHHs).

Authors:  Lise Schotte; Bert Thys; Mike Strauss; David J Filman; Bart Rombaut; James M Hogle
Journal:  Antimicrob Agents Chemother       Date:  2015-05-26       Impact factor: 5.191

5.  Structural Basis of Human Parechovirus Neutralization by Human Monoclonal Antibodies.

Authors:  Shabih Shakeel; Brenda M Westerhuis; Ari Ora; Gerrit Koen; Arjen Q Bakker; Yvonne Claassen; Koen Wagner; Tim Beaumont; Katja C Wolthers; Sarah J Butcher
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

6.  Five of Five VHHs Neutralizing Poliovirus Bind the Receptor-Binding Site.

Authors:  Mike Strauss; Lise Schotte; Bert Thys; David J Filman; James M Hogle
Journal:  J Virol       Date:  2016-01-13       Impact factor: 5.103

7.  Nanobody-mediated resistance to Grapevine fanleaf virus in plants.

Authors:  Caroline Hemmer; Samia Djennane; Léa Ackerer; Kamal Hleibieh; Aurélie Marmonier; Sophie Gersch; Shahinez Garcia; Emmanuelle Vigne; Véronique Komar; Mireille Perrin; Claude Gertz; Lorène Belval; François Berthold; Baptiste Monsion; Corinne Schmitt-Keichinger; Olivier Lemaire; Bernard Lorber; Carlos Gutiérrez; Serge Muyldermans; Gérard Demangeat; Christophe Ritzenthaler
Journal:  Plant Biotechnol J       Date:  2017-10-06       Impact factor: 9.803

8.  Nanobodies targeting norovirus capsid reveal functional epitopes and potential mechanisms of neutralization.

Authors:  Anna D Koromyslova; Grant S Hansman
Journal:  PLoS Pathog       Date:  2017-11-02       Impact factor: 6.823

9.  Biophysical insights from a single chain camelid antibody directed against the Disrupted-in-Schizophrenia 1 protein.

Authors:  Antony S K Yerabham; Andreas Müller-Schiffmann; Tamar Ziehm; Andreas Stadler; Sabrina Köber; Xela Indurkhya; Rita Marreiros; Svenja V Trossbach; Nicholas J Bradshaw; Ingrid Prikulis; Dieter Willbold; Oliver H Weiergräber; Carsten Korth
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

Review 10.  Single-Domain Antibodies As Therapeutics against Human Viral Diseases.

Authors:  Yanling Wu; Shibo Jiang; Tianlei Ying
Journal:  Front Immunol       Date:  2017-12-13       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.